Firy Inc. vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Firy Inc. trades at $11.97 (market cap $196.97M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 11.6× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| FIRY | SLS | |
|---|---|---|
Market Cap | $196.97M | $2.28B |
Volume | 155,239 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $13.10 | $15.46 |
52-Week Low | $2.28 | $1.39 |
Typical Hold Time | 13 Days | — |
Enterprise Value | $165.57M | $2.15B |
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.02, down 3.69% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company shows a high gross margin of 87.76% but negative net income margin of -60.23% and significant cash burn. Recent developments include a $719 million legal victory and board additions, though revenue has declined from $270M in 2022 to $104M in 2025.
The outlook remains challenging with persistent losses and cash burn offset by potential from legal wins. Investment opportunity exists if the company can monetize legal judgments and stabilize operations, but risks include continued operational losses and uncertainty around cash flow sustainability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →